While RxE2 continues promoting the practice of pharmacy and community-based pharmacists in clinical trials in the United States, the European Association of Hospital Pharmacies (EAHP) is encouraging the involvement of hospital pharmacists in European clinical trials. RxE2 applauds the EAHP for taking a position on clinical trials and their recognition of the valuable contributions pharmacists…
Fargo, ND, June 15, 2023 – This is the third year in which RxE2, led by CEO and two-time USA Cycling Masters National Cycling Champion, Gerald Finken, pledges $27,500 the NorthStar Cycling Club. “For over ten years NorthStar Development Cycling has shared the thrill of competitive cycling with scores of school-aged kids. Gerald Finken has…
RxE2 is disrupting the clinical supply chain to improve quality and eliminate waste – Meet us at #GCSG2023! Current supply chain logistics provide ample opportunity for risk and waste. What if we eliminate that? Led by Gerald E. Finken, the inventor of On-Demand Packaging & Labeling, RxE2 is de-risking the process by eliminating unnecessary steps for truly patient centric…
Diversity Now, the first protocol to achieve diversity in clinical trials according to the FDA guidelines for Race and Ethnicity Diversity Plans This plan provides a pharmacist-centered approach for compliance with Section V Categories 4 and 5 of the US Food and Drug Administration’s industry guidance (hereinafter “FDA Guidance”) for developing the required Race and…
Diversity in Clinical Trials – Background The Federal Drug Administration (FDA) issued non-compulsory guidance on clinical trial diversity to encourage diverse populations in clinical trials and improve the applicability of clinical trial results. The guidance recommends diverse clinical trial populations to better understand the safety and effectiveness of medical products across race, ethnicity, and gender.…
The Diversity Issue in Clinical Trials – an overview Pharmaceutical industry discussions on Diversity, Equity, and Inclusion (DEI) all end in the same place—the need to build patient trust. However, there are few suggestions about how to build this trust and little recognition that it will take time. Additionally, trust is only the first step…
Our team will be in San Francisco during the J.P. Morgan Healthcare Conference and is ready to meet with investors and industry leaders. We will also be taking part in the First Analysis Healthcare Technology Conference – 2023. Reach out to Gerald Finken or to David Stark to schedule a meeting!
Client A biopharmaceutical company sponsoring a Phase III clinical trial in the United States. Challenge The trial required the recruitment of patients with a neurological pain indication. The sponsor perceived a potential concern that patients had several alternative treatment options, including commercially available products, and therefore, may not be interested in a clinical study opportunity…
Fargo, ND, October 2022 RxE2 is happy to announce a recent investment from Badlands Capital. “I am so pleased to be working with Badlands Capital, especially since RxE2 is headquartered in Fargo, ND. The Badlands team truly understand what clinical trial innovation looks like and the magnitude of what RxE2 is and will accomplish, as we solve the recruitment, diversity,…
RxE2 is proud to be a member of the PQA, a non-profit organization with 250 diverse members across healthcare. Now more than ever we need to bring the practice of pharmacy into clinical trials. Incorporating PQA programs like Pharmacist Provided Care and Medication Use Quality will change the future outcomes for any clinical trial program…